Inverse Levels of Adiponectin in Type 1 and Type 2 Diabetes Are in Accordance with the State of Albuminuria

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2015 Jun 20

PMID 26089882

Citations 2

Authors

Spomenka Ljubic

Anamarija Jazbec

Martina Tomic

Ante Piljac

Dubravka Jurisic Erzen

Branko Novak

Snjezana Kastelan

Marijana Vucic Lovrencic

Neva Brkljacic

Affiliations

Soon will be listed here.

Abstract

Aims. To investigate the behaviour of adiponectin (ApN) in patients with type 1 and type 2 diabetic nephropathy. Methods. ApN and inflammatory and other markers of the metabolic syndrome were compared across diabetes types, albumin excretion rate (AER), and creatinine clearance (CrCl) categories in 219 type 1 and type 2 diabetic patients. Results. Significant differences among ApN levels according to AER were found in both types of diabetes (F = 8.45, df = 2, P < 0.001). With the progression of albuminuria, ApN increased in type 1 and decreased in type 2 diabetes. Patients with decreased CrCl had higher ApN levels than those with normal CrCl in either type of diabetes (F = 12.7, df = 1, P < 0.001). The best model for ApN (R (2) = 0.9002) obtained from stepwise regression in type 1 diabetes included CrCl, BMI, WBC, CRP, and age, while in type 2 diabetes (R (2) = 0.2882) it included ppPG, LDL, and UA. Conclusion. ApN behaved differently in relation to albuminuria, increasing with its progression in type 1 diabetes and decreasing in type 2 diabetes. It was however increased in the subgroups with decreased CrCl in both types of diabetes. Albuminuria seems to be more important than renal insufficiency in the definition of ApN levels in type 1 and type 2 diabetes.

Citing Articles

Plasma Adiponectin and Its Correlation with Carotid Intima-Media Thickness in Obesity and in Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.

Hussein M, Saif A, Amin M, Khalafallah O, Hussien A, Aboulsoud S J Nutr Metab. 2023; 2023:6661585.

PMID: 37692464 PMC: 10484655. DOI: 10.1155/2023/6661585.

Adiponectin receptor agonist AdipoRon ameliorates renal inflammation in diet-induced obese mice and endotoxin-treated human glomeruli ex vivo.

Lindfors S, Polianskyte-Prause Z, Bouslama R, Lehtonen E, Mannerla M, Nisen H Diabetologia. 2021; 64(8):1866-1879.

PMID: 33987714 PMC: 8245393. DOI: 10.1007/s00125-021-05473-9.

References

Zoccali C, Mallamaci F, Tripepi G, Benedetto F, Cutrupi S, Parlongo S . Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2001; 13(1):134-141. DOI: 10.1681/ASN.V131134. View

Langouche L, Vander Perre S, Wouters P, dHoore A, Hansen T, Van den Berghe G . Effect of intensive insulin therapy on insulin sensitivity in the critically ill. J Clin Endocrinol Metab. 2007; 92(10):3890-7. DOI: 10.1210/jc.2007-0813. View

Brooks N, Moore K, Clark R, Perfetti M, Trent C, Combs T . Do low levels of circulating adiponectin represent a biomarker or just another risk factor for the metabolic syndrome?. Diabetes Obes Metab. 2007; 9(3):246-58. DOI: 10.1111/j.1463-1326.2006.00596.x. View

Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E . Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?. J Clin Endocrinol Metab. 2001; 86(7):3257-65. DOI: 10.1210/jcem.86.7.7623. View

Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D . Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant. 2004; 20(1):129-34. DOI: 10.1093/ndt/gfh568. View

Yilmaz M, Saglam M, Qureshi A, Carrero J, Caglar K, Eyileten T . Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant. 2008; 23(5):1621-7. DOI: 10.1093/ndt/gfm828. View

Hayden M, Tyagi S . Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond). 2004; 1(1):10. PMC: 529248. DOI: 10.1186/1743-7075-1-10. View

Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K . Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004; 43(6):1318-23. DOI: 10.1161/01.HYP.0000129281.03801.4b. View

Yaturu S, Bridges J, Subba Reddy D . Decreased levels of plasma adiponectin in prediabetes, Type 2 diabetes and coronary artery disease. Med Sci Monit. 2005; 12(1):CR17-20. View

10.

Komura N, Kihara S, Sonoda M, Maeda N, Tochino Y, Funahashi T . Increment and impairment of adiponectin in renal failure. Cardiovasc Res. 2009; 86(3):471-7. DOI: 10.1093/cvr/cvp415. View

11.

Saraheimo M, Forsblom C, Thorn L, Waden J, Rosengard-Barlund M, Heikkila O . Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care. 2008; 31(6):1165-9. DOI: 10.2337/dc07-2306. View

12.

Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M . Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003; 107(5):671-4. DOI: 10.1161/01.cir.0000055188.83694.b3. View

13.

Pischon T, Girman C, Hotamisligil G, Rifai N, Hu F, Rimm E . Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 291(14):1730-7. DOI: 10.1001/jama.291.14.1730. View

14.

Yokoyama H, Moriya S, Homma Y, Ogawa T . Association between gamma-glutamyl transpeptidase activity and status of disorders constituting insulin resistance syndrome. Alcohol Clin Exp Res. 2003; 27(8 Suppl):22S-25S. DOI: 10.1097/01.ALC.0000078608.22813.D9. View

15.

Ridker P, Rifai N, Rose L, Buring J, Cook N . Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347(20):1557-65. DOI: 10.1056/NEJMoa021993. View

16.

Schalkwijk C, Chaturvedi N, Schram M, Fuller J, Stehouwer C . Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab. 2005; 91(1):129-35. DOI: 10.1210/jc.2005-1117. View

17.

Shetty G, Economides P, Horton E, Mantzoros C, Veves A . Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004; 27(10):2450-7. DOI: 10.2337/diacare.27.10.2450. View

18.

Seshadri N, Messerli A, Acharya N, Pearce G, Jacobsen D, Pohl M . Relation of homocysteine and C-reactive protein to urinary albumin loss. Am J Cardiol. 2004; 93(7):926-8. DOI: 10.1016/j.amjcard.2003.12.038. View

19.

Zografos T, Liaskos C, Rigopoulou E, Togousidis E, Makaritsis K, Germenis A . Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am J Gastroenterol. 2008; 103(3):605-14. DOI: 10.1111/j.1572-0241.2007.01729.x. View

20.

Ran J, Xiong X, Liu W, Guo S, Li Q, Zhang R . Increased plasma adiponectin closely associates with vascular endothelial dysfunction in type 2 diabetic patients with diabetic nephropathy. Diabetes Res Clin Pract. 2010; 88(2):177-83. DOI: 10.1016/j.diabres.2010.01.021. View